Aroa BiosurgeryASX:ARX +0.85%62 FCF Yield % is 2.78 as of Jun. 27, 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 68.54% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Aroa Biosurgery's FCF Yield % or its related term are showing as below:
ASX:ARX'
s FCF Yield % Range Over the Past 10 Years
Min: -8.71 Med: -3.74 Max: 3.14
Current: 2.78
During the past 7 years, the highest FCF Yield % of Aroa Biosurgery was 3.14%. The lowest was -8.71%. And the median was -3.74%.
ASX:ARX's FCF Yield % is ranked better than 68.54% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.38
vs ASX:ARX: 2.78
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Aroa Biosurgery FCF Yield % Related Terms
Aroa Biosurgery FCF Yield % Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a FCF Yield % of 2.78 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #269 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 31.5%.
Is Aroa Biosurgery's FCF Yield % too high?
Aroa Biosurgery's current FCF Yield % is 2.78. Based on the distribution chart, Aroa Biosurgery ranks #269 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #269 out of 855 companies for FCF Yield %. This puts Aroa Biosurgery in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current FCF Yield % is 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current FCF Yield % is 2.78. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current FCF Yield % is 2.78 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
FCF Yield %: 2.78
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
